The Catalan Society of Infectious Diseases and Clinical Microbiology (SCMIMC) has awarded one of its pre-doctoral grants to Dr. Elena Sendra, a consultant in Hospital del Mar's Infectious Diseases Service. This is a biannual grant that will allow her to develop her doctoral thesis project. The grant was awarded during the XXX Meeting of the society, held on 15th and 16th October in Sitges, Garraf.
19/10/2021 - Press release
Activating a molecule present in the membrane of NK lymphocytes (Natural Killer cells) makes them resistant to the immunosuppressive mechanisms of HER2-positive breast tumours and enhances their antitumour action. Combining standard treatments for HER2-positive breast cancer with drugs that target this molecule in NK cells could increase their clinical efficacy. This paves the way for a new approach to treating this type of tumour with immunotherapy This has been demonstrated in a collaborative study led by researchers at the Hospital del Mar Medical Research Institute, published in the journal Cancer Immunology Research
05/10/2021 - General information
With this new group, the Carlos III Health Institute's Networked Biomedical Research Centre aims to unite Spain's scientific excellence in this field to enable better funding in emerging diseases, such as COVID-19, and other research areas, including antimicrobial resistance and HIV-AIDS, in which Hospital del Mar and IMIM researchers have a great deal of experience. The Infectious Pathology and Antimicrobial Research Group (IPAR) at the Hospital de Mar Medical Research Institute (IMIM) will form part of the new CIBER on Infectious Diseases. The purpose of this new group is to promote research in this field in Spain by offering new structural funding tools.
Més informació "Hospital del Mar and IMIM to participate in the new CIBER on infectious diseases"
1/10/2021 - Press release
Patients with chronic obstructive pulmonary disease (COPD) who also suffer from a blood iron deficiency significantly improve their physical fitness if they receive supplements of this mineral. This is a new approach to the disease, which has been validated by the first studies published in Spain in this field and the largest in the world, to date, involving 66 patients. The work, derived from the FACE-Ferinject Assessment study on improving Exercise Tolerance in patients suffering COPD and iron deficiency, was carried out by doctors and researchers in the Pneumology Department at Hospital del Mar and the Hospital del Mar Medical Research Institute (IMIM) and has been published in the journals Archivos de Bronconeumología and Biomedicines.
Més informació "Iron supplements improve physical fitness and quality of life in COPD patients"
29/09/2021 - Institutional news
Doctors Juan Pablo Horcajada and Robert Güerri are part of this committee, which was officially constituted yesterday. This body will begin its work with 32 people associated with scientific knowledge from various professions and fields and will operate with independent criteria. Its task is to offer technical advice on different actions to be taken to control the pandemic. Yesterday, the Department of Health officially established the COVID-19 Scientific Advisory Committee, a body created to provide independent advice on the different pandemic-control actions in Catalonia. Among its 32 founding members is Dr. Juan Pablo Horcajada, head of the Infectious Diseases Service at Hospital del Mar and coordinator of the Infectious Pathology and Antimicrobial Research Group (IPAR) at the Hospital del Mar Medical Research Institute (IMIM); In addition to Dr. Robert Güerri, section head of the Infectious Diseases Service and an IMIM researcher.
13/09/2021 - General information
The editorial team of this prestigious publication, the third most important in respiratory medicine according to impact factor, has invited the consultant physician from the Pneumology Department and researcher at the Hospital del Mar Medical Research Institute, to collaborate with them. Dr. Esther Barreiro has joined the editorial team at the European Respiratory Society, as Associate Editor of the European Respiratory Journal (ERJ). Her role involves assisting the journal's senior editors to select potentially interesting manuscripts for publication, as well as inviting reviewers and providing advice on publication decisions. She will also write editorials for publication.
19/05/2021 - General information
The consultant in the Pneumology Department at Hospital del Mar and Hospital del Mar Medical Research Institute researcher will be at the helm of this prestigious publication for the next three years. Dr. Esther Barreiro, a consultant in the Pneumology Service at Hospital del Mar and coordinator of the IMIM's Research Group on Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer, will be the new editor-in-chief of ERJ Open Research, the official journal of the European Respiratory Society (ERS). Her appointment was announced at the last meeting of the ERS Executive Committee and will take effect in January 2022.
04/03/2021 - Covid-19
Administering zinc supplements to covid-19 patients with low levels of this element may be a strategy to reduce mortality and recovery time. At the same time, it could help to prevent risk groups, like the elderly, from suffering the worst effects of the disease. These are the findings of a study by physicians and researchers from the Hospital del Mar, Hospital del Mar Medical Research Institute (IMIM) and Pompeu Fabra University (UPF), led by Dr. Robert Güerri, a physician at the Infectious Diseases Service of Hospital del Mar, which has just been published in the journal Nutrients. The study analysed the zinc levels of 249 adult patients treated at the centre between 9 March and 1 April 2020, with an average age of 65 years. The most common symptoms presented at the time of admission were fever, cough and dyspnea.
Més informació "Administering zinc to covid-19 patients could help towards their recovery"
18/02/2021 - Covid-19
The Hospital del Mar Medical Research Institute (IMIM), Hospital del Mar, the University of California-Davis and the University of Texas have launched a clinical trial to analyse how useful a food supplement can be for preventing the worst side effects of COVID-19. The study is looking at bovine-derived immunoglobulins, which have been shown in animal models to reduce the inflammation caused by infection, progression to more severe forms of the disease, and post-COVID syndrome. The first patients participating in the Randomized Open-Label Clinical Study Evaluating the Impact of EnteraGam, a Nutritional Intervention containing Bovine Plasma-Derived Immunoglobulin CoNcentrate, on Clinical Outcomes In People with COVID19 (PICNIC Study) are already taking two daily doses of this supplement. Dr Robert Güerri, principal investigator in the trial, member of the Infectious Pathology and Antimicrobial Research Group at the IMIM-Hospital del Mar, and section head of the Infectious Diseases Service at Hospital del Mar, explains that "The aim of the treatment is to sequester and help eliminate the virus from one of its main reservoirs in the body, the gut."
Més informació "Immunoglobulin clinical trial launched to prevent COVID-19 side effects"
15/12/2020 - Press release
DNA damage levels and the activity of the polymerase enzyme responsible for cell repair (PARP) increase in lung tumours in patients suffering chronic obstructive pulmonary disease (COPD), but not in people who do not have this pathology. This is reflected in work by researchers from the CIBER of Respiratory Diseases (CIBERES) and doctors and researchers from the Hospital del Mar Pneumology Service and the Hospital del Mar Medical Research Institute research group on muscle wasting and cachexia in chronic respiratory diseases and lung cancer (IMIM-Hospital del Mar), published in the journal Cancers This research is of enormous importance given that treating lung cancer with PARP enzyme inhibitors (already in clinical use for other tumours, such as breast and ovarian cancers) is preferentially indicated for patients with an underlying respiratory disease, while the response in people with no COPD is highly controversial.
Més informació "The presence of COPD, a determining factor in lung cancer treatment"
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
